The effects and efficacy of Imaavy (nipocalimab-aahu)

Imaavy (nipocalimab-aahu), as a human IgG1 monoclonal antibody, exerts its therapeutic effect and efficacy mainly by binding to the neonatal Fc receptor (FcRn). Its mechanism of action is to reduce the level of immunoglobulin G (IgG) antibodies circulating in the body by binding to FcRn with high affinity, thereby improving the symptoms and daily functions of patients with myasthenia gravis (gMG).

In systemic myasthenia gravis, an autoimmune disease, a patient's immune system mistakenly produces harmful antibodies that target the neuromuscular junction, specifically antibodies against the acetylcholine receptor (AChR) or against muscle-specific kinase (MuSK). The presence of these antibodies can lead to impairments in nerve signaling, leading to symptoms such as muscle weakness and fatigue. By blocking the function of FcRn, Imaavy accelerates the decomposition rate of these IgG antibodies and reduces their retention in the body, thereby reducing damage to the nervous system.

Specifically, FcRn plays an important role in maintaining the stability of IgG antibodies and extending their half-life. Under normal circumstances, after FcRn binds to IgG, it protects IgG from being degraded by the intracellular degradation mechanism. However, Imaavy significantly shortens the survival time of IgG antibodies by binding to FcRn and blocking this process. This mechanism effectively reduces the level of harmful IgG in the body, thereby alleviating the autoimmune response and improving the patient's condition.

Clinical studies have shown that Imaavy has good efficacy in the treatment of myasthenia gravis and can significantly improve the quality of life of patients. For adult and pediatric patients 12 years and older who are positive for anti-AChR or MuSK antibodies, Imaavy provides a new treatment option to help them better control their disease and improve their ability to perform daily activities. In addition, because Imaavy's mechanism of action is different from traditional treatments, it offers new hope for patients who have not responded well to existing treatments.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8886274c-f2b2-48af-85c1-2f90bfe304b8##